The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population

The Military Medical Consortium for Applied Retroviral Research

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

As the focus of the management of human immunodeficiency virus (HIV) infection turns from the treatment of AIDS to the entire continuum of the disease, projection of long-term healthcare costs becomes increasingly important. Rather than a fulminant disease treated primarily inside the hospital, HIV infection will become a chronic condition requiring years of outpatient monitoring and pharmacologic intervention with attending increases in pharmacy costs. The objective of this study was to characterize outpatient drug costs by Walter Reed (WR) disease stage in order to estimate the association of disease progression and outpatient prescription drug costs. We hypothesized that there was an association between HIV disease progression, measured by the WR Staging Classification System, and outpatient prescription drug costs. Outpatient drug costs were summarized for 190 HIV-positive patients during a three-month period who presented at Walter Reed Army Medical Center for staging and follow-up. The overall median cost per day per patient for all stages was $3.21 (range $0.01–53.45) with wide variation between patients. Daily costs for patients in WR stage V were the greatest (median $9.26). There was a significant association between WR stage of disease and outpatient drug costs (Spearman rho = 0.51, t = 6.9, df = 188, p<0.001). The association was not completely linear because costs in WR stage VI were less than WR stages IV or V. Annual extrapolated outpatient drug costs for these 190 patients would be nearly $0.5 million.

Original languageEnglish (US)
Pages (from-to)414-417
Number of pages4
JournalAnnals of Pharmacotherapy
Volume25
Issue number4
DOIs
StatePublished - 1991

Fingerprint

Cost of Illness
Drug Costs
Disease Progression
Outpatients
HIV
Virus Diseases
Population
Costs and Cost Analysis
Prescription Drugs
Ambulatory Monitoring
Health Care Costs
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population. / The Military Medical Consortium for Applied Retroviral Research.

In: Annals of Pharmacotherapy, Vol. 25, No. 4, 1991, p. 414-417.

Research output: Contribution to journalArticle

The Military Medical Consortium for Applied Retroviral Research. / The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population. In: Annals of Pharmacotherapy. 1991 ; Vol. 25, No. 4. pp. 414-417.
@article{d5313b6eba534f1bb0c148bdb0aa5c39,
title = "The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population",
abstract = "As the focus of the management of human immunodeficiency virus (HIV) infection turns from the treatment of AIDS to the entire continuum of the disease, projection of long-term healthcare costs becomes increasingly important. Rather than a fulminant disease treated primarily inside the hospital, HIV infection will become a chronic condition requiring years of outpatient monitoring and pharmacologic intervention with attending increases in pharmacy costs. The objective of this study was to characterize outpatient drug costs by Walter Reed (WR) disease stage in order to estimate the association of disease progression and outpatient prescription drug costs. We hypothesized that there was an association between HIV disease progression, measured by the WR Staging Classification System, and outpatient prescription drug costs. Outpatient drug costs were summarized for 190 HIV-positive patients during a three-month period who presented at Walter Reed Army Medical Center for staging and follow-up. The overall median cost per day per patient for all stages was $3.21 (range $0.01–53.45) with wide variation between patients. Daily costs for patients in WR stage V were the greatest (median $9.26). There was a significant association between WR stage of disease and outpatient drug costs (Spearman rho = 0.51, t = 6.9, df = 188, p<0.001). The association was not completely linear because costs in WR stage VI were less than WR stages IV or V. Annual extrapolated outpatient drug costs for these 190 patients would be nearly $0.5 million.",
author = "{The Military Medical Consortium for Applied Retroviral Research} and McGhan, {William F.} and Bootman, {J Lyle} and Townsend, {Raymond J.} and Bjornson, {Darrel C.} and Oster, {Charles N.} and Hiner, {William O.} and Tramont, {Edmund C.}",
year = "1991",
doi = "10.1177/106002809102500415",
language = "English (US)",
volume = "25",
pages = "414--417",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "4",

}

TY - JOUR

T1 - The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population

AU - The Military Medical Consortium for Applied Retroviral Research

AU - McGhan, William F.

AU - Bootman, J Lyle

AU - Townsend, Raymond J.

AU - Bjornson, Darrel C.

AU - Oster, Charles N.

AU - Hiner, William O.

AU - Tramont, Edmund C.

PY - 1991

Y1 - 1991

N2 - As the focus of the management of human immunodeficiency virus (HIV) infection turns from the treatment of AIDS to the entire continuum of the disease, projection of long-term healthcare costs becomes increasingly important. Rather than a fulminant disease treated primarily inside the hospital, HIV infection will become a chronic condition requiring years of outpatient monitoring and pharmacologic intervention with attending increases in pharmacy costs. The objective of this study was to characterize outpatient drug costs by Walter Reed (WR) disease stage in order to estimate the association of disease progression and outpatient prescription drug costs. We hypothesized that there was an association between HIV disease progression, measured by the WR Staging Classification System, and outpatient prescription drug costs. Outpatient drug costs were summarized for 190 HIV-positive patients during a three-month period who presented at Walter Reed Army Medical Center for staging and follow-up. The overall median cost per day per patient for all stages was $3.21 (range $0.01–53.45) with wide variation between patients. Daily costs for patients in WR stage V were the greatest (median $9.26). There was a significant association between WR stage of disease and outpatient drug costs (Spearman rho = 0.51, t = 6.9, df = 188, p<0.001). The association was not completely linear because costs in WR stage VI were less than WR stages IV or V. Annual extrapolated outpatient drug costs for these 190 patients would be nearly $0.5 million.

AB - As the focus of the management of human immunodeficiency virus (HIV) infection turns from the treatment of AIDS to the entire continuum of the disease, projection of long-term healthcare costs becomes increasingly important. Rather than a fulminant disease treated primarily inside the hospital, HIV infection will become a chronic condition requiring years of outpatient monitoring and pharmacologic intervention with attending increases in pharmacy costs. The objective of this study was to characterize outpatient drug costs by Walter Reed (WR) disease stage in order to estimate the association of disease progression and outpatient prescription drug costs. We hypothesized that there was an association between HIV disease progression, measured by the WR Staging Classification System, and outpatient prescription drug costs. Outpatient drug costs were summarized for 190 HIV-positive patients during a three-month period who presented at Walter Reed Army Medical Center for staging and follow-up. The overall median cost per day per patient for all stages was $3.21 (range $0.01–53.45) with wide variation between patients. Daily costs for patients in WR stage V were the greatest (median $9.26). There was a significant association between WR stage of disease and outpatient drug costs (Spearman rho = 0.51, t = 6.9, df = 188, p<0.001). The association was not completely linear because costs in WR stage VI were less than WR stages IV or V. Annual extrapolated outpatient drug costs for these 190 patients would be nearly $0.5 million.

UR - http://www.scopus.com/inward/record.url?scp=0025726707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025726707&partnerID=8YFLogxK

U2 - 10.1177/106002809102500415

DO - 10.1177/106002809102500415

M3 - Article

C2 - 1926913

AN - SCOPUS:0025726707

VL - 25

SP - 414

EP - 417

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 4

ER -